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Preface
Advances in treatment of chronic myeloid leukemia (CML) have been made over
the past two decades thanks to research that has furthered our understanding of its
molecular pathogenesis. CML is a clonal hematopoietic stem cell disorder charac-
terized by the abnormal proliferation of myeloid cell lineages, which progresses
through the chronic phase (CP) to the accelerated and blastic phases. CML is caused
by the presence of the Philadelphia (Ph) chromosome in hematopoietic stem cells,
which arises from the reciprocal translocation of chromosomes 9 and 22, t(9;22)
(q34;q11), resulting in the development of the bcr-abl chimeric gene. This chimeric
gene produces the BCR-ABL fusion protein that has oncogenic activity. The
BCR-ABL fusion protein has constitutive tyrosine kinase (TK) activity that is
stronger than that of the naı̈ve ABL protein, conferring a proliferative advantage
and aberrant differentiation capacity to affected hematopoietic stem cells, resulting
in the oncogenic event of leukemia development. Therefore, formation of the bcr-
abl chimeric gene and its encoded protein is a primary and central event in the
molecular pathogenesis of CML.
Until 2000, drug therapy for CML was limited to non-specific cytotoxic drugs
such as busulfan and hydroxyurea, and then interferon (IFN)-α was introduced to
regress disease activity, which had a survival benefit. Allogeneic hematopoietic
stem cell transplantation (allo-SCT) for CML-CP frequently was a curative thera-
peutic approach for patients with good performance status and an appropriate stem
cell donor, but it also was associated with a high incidence of early morbidity and
mortality. Understanding of the molecular pathogenesis of CML resulted in rapid
development of new therapeutic agents, including various BCR-ABL specific
tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib. Current
clinical guidelines endorse use of any of these three TKIs for initial management of
CML-CP. Molecular-targeted therapy with these TKIs was shown to dramatically
improve clinical outcomes of CML patients, increasing the 10-year overall survival
(OS) from 20 to 80–90 %. As shown in many clinical studies, CML patients treated
with TKIs are expected to live for a long period of time. Thus, identification of
appropriate surrogate markers for clinical outcome has become important.
v
Achieving a more complete and faster molecular response is correlated with good
clinical outcome; therefore, improving molecular monitoring techniques for mini-
mal residual disease is crucial. Furthermore, management of TKI-resistant CML
and development of new TKIs are also important issues. We now have available
multiple TKIs for clinical use, including second- and third-generation agents. In
this decade, our goals for the treatment of CML are to optimize the quality of life for
patients, to establish the most cost-effective treatment, and to deliver the best
treatment and monitoring to each patient anywhere in the world. The ultimate
goal for any patient is to discontinue use of TKIs—to achieve treatment-free
remission and subsequent cure. In other words, future research into treatment of
CML will focus on achieving and maintaining complete molecular remission after
discontinuation of TKIs.
This book begins with a discussion of recent advances in basic CML research
regarding stem cells and the signaling pathways of leukemic cells; continues by
describing various clinical aspects of the use of TKIs in daily clinical practice; and
concludes with a discussion of future trials aimed at a cure for this disease. I would
like to acknowledge the many excellent colleagues who have contributed to each
chapter. In addition, I would like to express my appreciation to the staff of Springer
Japan, for all of their efforts in bringing this treatise to publication. It is hoped that
this book will encourage implementation of further basic and clinical research
projects with the goal of solving the remaining intriguing and important clinical
problems of CML treatment.
Kawagoe, Japan Masahiro Kizaki, MD, PhD
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